Unique Hemoglobinopathy Pattern Following Treatment with Voxelotor

Area of Science:

• Hematology
• Pharmacology
• Pediatric Medicine

Background:

• Voxelotor is FDA-approved for sickle cell disease (SCD), inhibiting HbS polymerization and reducing hemolysis.
• Voxelotor alters hemoglobin fractionation patterns, impacting interpretation.
• Assessing voxelotor's effect on hemolysis markers in pediatric SCD patients is crucial.

Purpose of the Study:

• To evaluate if voxelotor-induced changes in hemoglobin fractionation correlate with improved hemolysis markers in pediatric SCD patients.
• To explore the utility of hemoglobin fractionation in monitoring voxelotor treatment.

Main Methods:

• Analyzed 15 pediatric patients (12-20 years) on voxelotor.
• Compared hemoglobin fractionation, total hemoglobin, reticulocyte percentage, LDH, and bilirubin before and after voxelotor initiation.
• Utilized capillary electrophoresis for hemoglobin fractionation.

Main Results:

• Hemoglobin fractionation profile changes observed in 60% (9/15) of patients.
• 44% (4/9) of patients with fractionation changes showed >1 g/dL increase in total hemoglobin.
• Decreased LDH (4/4), reticulocyte percentage (6/8), and bilirubin (3/4) were observed.

Conclusions:

• Hemoglobin fractionation analysis in voxelotor-treated SCD patients reveals unique patterns.
• These patterns may serve as a tool to assess patient response and compliance to voxelotor therapy.
• Further research can validate hemoglobin fractionation as a monitoring tool for voxelotor treatment efficacy.